What factors influence your decision to switch a patient from alglucosidase alfa to avalglucosidase alfa?

What challenges do clinicians face in monitoring disease progression and response to therapy?

How has avalglucosidase alfa impacted the treatment paradigm for both infantile-onset and late-onset Pompe disease in your experience?

What challenges do clinicians face in monitoring in disease progrission and response to therapy?